#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	11912	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2194	535.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1521	1521	C	668	C,T,G	656,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	11912	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2194	535.6	0	HET	.	.	.	C207T	.	207	207	C	544	544	C	665	C,T	513,120	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21606	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3623	591.3	0	.	n	.	0	T695C	SNP	695	695	T	1024	1024	C	651	C,T,A	642,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21606	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3623	591.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	1967	1967	G	696	G,A	340,346	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21606	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3623	591.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2300	2300	C	690	C	673	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21606	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3623	591.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2374	2374	A	720	A	711	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21606	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3623	591.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2926	2926	C	620	C	614	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1626	folP	855	855	100.0	folP.l15.c4.ctg.1	1802	89.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1059	1061	AGC	158;161;162	A;G;C	157;161;161	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4246	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3384	124.1	1	SNP	p	S91F	1	.	.	271	273	TTC	563	565	TTC	161;160;159	T;T;C	157;155;151	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4246	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3384	124.1	1	SNP	p	D95G	1	.	.	283	285	GGC	575	577	GGC	160;156;157	G,A;G;C	155,1;151;153	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4246	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3384	124.1	1	SNP	p	G95N	0	.	.	283	285	GGC	575	577	GGC	160;156;157	G,A;G;C	155,1;151;153	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1380	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1552	88.1	1	SNP	p	G45D	0	.	.	133	135	GGC	586	588	GGC	140;140;140	G;G;C	136;137;136	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	714	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1079	65.2	0	.	n	.	0	A197.	DEL	197	197	A	657	657	A	157	A	154	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3754	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2967	125.2	1	SNP	p	D86N	0	.	.	256	258	GAC	552	554	GAC	134;136;137	G;A;C	131;130;135	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3754	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2967	125.2	1	SNP	p	R87I	0	.	.	259	261	CGT	555	557	CGT	136;134;133	C;G;T	135;133;128	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3754	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2967	125.2	1	SNP	p	S87R	1	.	.	259	261	CGT	555	557	CGT	136;134;133	C;G;T	135;133;128	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3754	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2967	125.2	1	SNP	p	R87W	0	.	.	259	261	CGT	555	557	CGT	136;134;133	C;G;T	135;133;128	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3754	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2967	125.2	1	SNP	p	S88P	0	.	.	262	264	TCC	558	560	TCC	132;133;132	T;C;C,T	130;131;130,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3298	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2810	116.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1533	1535	GGC	155;148;149	G;G;C	152;147;145	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	A311V	0	.	.	931	933	GCC	1259	1261	GCC	190;190;188	G;C;C,A	183;186;186,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	I312M	1	.	.	934	936	ATG	1262	1264	ATG	189;188;185	A;T,A;G	189;185,1;181	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	T316P	0	.	.	946	948	ACC	1274	1276	ACC	186;181;180	A,T;C;C	180,1;180;179	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	V316T	1	.	.	946	948	ACC	1274	1276	ACC	186;181;180	A,T;C;C	180,1;180;179	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1775	1777	ACC	164;164;164	A;C;C	156;159;160	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1829	1831	GCG	164;166;166	G;C;G	162;164;164	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1829	1831	GCG	164;166;166	G;C;G	162;164;164	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1952	1954	GGT	127;126;126	G;G;T	126;125;123	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1961	1963	AGC	120;120;119	A;G;C	118;118;117	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3268	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2392	134.9	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1979	1981	CCG	91;94;95	C,G,A;C,G;G	85,1,1;87,1;82	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4466	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3186	138.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1655	1657	CCG	143;143;145	C;C,T,G;G	133;140,1,1;139	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1878	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1876	98.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	599	599	C	108	C	101	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2346	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1742	133.5	0	.	p	.	0	I45V	NONSYN	133	135	ATT	538	540	GTT	170;170;171	G;T;T	168;167;170	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2346	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1742	133.5	1	SNP	p	G120K	1	.	.	358	360	AAG	763	765	AAG	172;168;169	A,C;A;G	166,1;165;156	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2346	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1742	133.5	1	SNP	p	A121N	1	.	.	361	363	AAC	766	768	AAC	171;173;169	A;A;C	165;167;162	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2346	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1742	133.5	1	SNP	p	N121D	0	.	.	361	363	AAC	766	768	AAC	171;173;169	A;A;C	165;167;162	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7848	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	5059	154.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	882	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1279	68.2	1	SNP	p	V57M	1	.	.	169	171	ATG	681	683	ATG	169;167;167	A;T;G,A	168;167;165,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
